Cerevance is working to change that. Proprietary
technology that accurately determines brain age and
relates it to Alzheimer’s, Parkinson’s, and other brain
diseases is providing novel insights that inform therapeutic development

Durect focuses on eliminating the epigenetic faults that cause cells to become dysfunctional. Following this approach, Durect intends to generate drugs that can treat acute organ injury and chronic liver diseases.

Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.

Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.

Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help bankroll development of the drug. 

“Fountain is an example of a biotech company emerging as a direct result of basic research, in this case the biology of aging,” said Dr Rando, founder and chairman of Fountain. “The company’s screening and discovery platform is built upon foundational research showing that the age of a cell can be modulated by factors in the cell’s environment. By identifying compounds that work through these pathways, we seek to restore youthful resilience to cells and tissues, leading to therapies that treat or even prevent chronic diseases of aging.”

When you’re heading up a fledgling biotech out to make a name for yourself in the middle of a wild industry boom, there’s one sure way to differentiate yourself that’s bound to attract universal nods.